Johnson and Johnson report favourable safety profile for Invega

Johnson & Johnson (J&J) has reported new data which shows that its Invega extended-release tablets show favourable long-term safety and tolerability during a one-year open-label extension study.

The study was intended to evaluate the long-term safety of J&J’s anti-psychotic product Invega, which is approved for the treatment of schizophrenia.

Results demonstrated that discontinuations due to treatment-emergent adverse events (TEAEs) and the total number of serious TAEAs were both at six per cent.

In addition, there was no significant mean change recorded for other assessments such as cardio-vascular, metabolic or weight-related events.

Patient symptom scores were also shown to be improved with symptoms of schizophrenia reduced in those patients transitioned from placebo to Invega.

George M Simpson, professor or research at the Keck School of Medicine of the University of Southern California, commented: “This long-term extension trial adds to the body of knowledge regarding the safety of Invega in the longer-term treatment of schizophrenia.”

He went on to outline that symptom control of schizophrenia was maintained over time for those patients who were previously on Invega.

Earlier this month, J&J announced positive phase III data showing that rivaroxaban was statistically superior to enoxaparin when used to prevent venous thromboembolism in patients who had undergone hip replacement surgery.